title: [Use of furamag to prevent inflammatory complications during endoscopic operations in patients with benign prostatic hyperplasia and urolithiasis].
abstract: OBJECTIVE
  To improve surgical results in patients with benign prostatic hyperplasia (BPH) and urolithiasis (UL) and to evaluate the efficacy of Furamag used as an agent to prevent infectious and inflammatory complications.
  
  
  METHODS
  Seventy-two patients with BPH (n = 36; Group 1) and UL (n = 36; Group 2) were examined. Within each group, the patients were divided into two subgroups: A) those in whom no preventive measures were taken during endoscopic operations; B) those who received Furamag as a preventive agent. The preventive efficacy was evaluated from the urine microbial spectrum and renal microcirculatory values.
  
  
  RESULTS
  The preventive use of Furamag could achieve better urine sanitation, normalize renal microcirculatory values, and reduce the incidence of postoperative complications.
  
  
  CONCLUSIONS
  The use of Furamag to prevent intravesical obstruction (IVO) during transurethral prostatic resection and UL reduces the incidence of IVO, results in less noticeable renal microcirculatory disorders, and accordingly assists in lowering the incidence of postoperative complications.
authors.forename: A I
authors.initials: AI
authors.lastname: Neĭmark
authors.forename: A V
authors.initials: AV
authors.lastname: Simashkevich
mesh_terms: D004724:Endoscopy; D005650:Fumarates / Q000627:therapeutic use*; D006801:Humans; D007249:Inflammation / Q000188:drug therapy / Q000382:microbiology / Q000517:prevention & control; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications / Q000188:drug therapy / Q000382:microbiology / Q000517:prevention & control*; D011470:Prostatic Hyperplasia / Q000188:drug therapy / Q000382:microbiology / Q000601:surgery; D016896:Treatment Outcome; D052878:Urolithiasis / Q000188:drug therapy / Q000382:microbiology / Q000601:surgery
chemical_list: D005650:Fumarates; C032005:fumaric acid